HOME >> MEDICINE >> NEWS
Should the standard guidelines for assessing prostate cancer control be changed?

The specificity and sensitivity of the ASTRO definition to predict clinical failure was 60 percent and 72 percent, respectively. Again, using three alternate definitions of clinical failure, the researchers demonstrated specificity and sensitivity results of 67 and 78 percent, 66 and 77 percent, and 64 and 74 percent.

"These alternate definitions potentially offer more accuracy in predicting who will remain free of cancer after treatment and who will truly develop metastatic disease based on a patient's post-treatment PSA levels," Horwitz said. "What's more, these results add to the current discussion in the radiation oncology community and to the body of evidence suggesting modifications to the standard ASTRO definition to predict treatment failure."

Other authors of the study include Howard D. Thames, Ph.D., department of biomathematics, University of Texas M. D. Anderson Cancer Center, Houston; Deborah A. Kuban M.D., division of radiation oncology, University of Texas M. D. Anderson Cancer Center; Larry B. Levy, M.S., department of biomathematics, University of Texas M. D. Anderson Cancer Center; Patrick A. Kupelian, M.D., department of radiation oncology, The Cleveland Clinic Foundation, Cleveland, Ohio; Alvaro A. Martinez, M.D., William Beaumont Hospital, Royal Oak, Mich.; Jeffrey M. Michalski, M.D., department of radiation oncology, Mallinckrodt Institute of Radiology, St. Louis, Mo.; Thomas M. Pisansky M.D., division of radiation oncology, Mayo Clinic, Rochester Minn.; Howard M. Sandler, M.D., department of radiation oncology, University of Michigan, Ann Arbor; William U. Shipley, M.D., department of radiation oncology, Massachusetts General Hospital, Boston; Michael J. Zelefsky, M.D., department of radiation oncology, Memorial Sloan-Kettering Cancer Center, New York City; Gerald E. Hanks, M.D., retired from the department of radiation oncology, Fox Chase Cancer Center, Philadelphia, Pa.; and Anthony L. Zietman, M.D., department of radiation
'"/>

Contact: Karen Carter Mallet
k_carter@fccc.edu
215-728-2700
Fox Chase Cancer Center
20-Oct-2003


Page: 1 2 3

Related medicine news :

1. Should medical students have earlier contact with patients?
2. Should nurses conduct breast cancer follow-up visits?
3. Should compulsory screening of immigrants be part of UK public health policy?
4. Should living liver donation be available in the NHS?
5. Should ambulance crews perform emergency breathing procedure?
6. C-reactive proteins: Should everyone be tested?
7. Should people with dementia be electronically tagged?
8. Should we help to create disabled babies?
9. Should people with diabetes sleep with the lights on?
10. Should women be screened for domestic violence?
11. Should banks be liable for pollution caused by companies that borrow from them?

Post Your Comments:
(Date:4/23/2014)... "simple and accessible detection methods that can rapidly ... of a single cell inside that population has ... Chang Lu. , In the Royal Society of ... announced that he and his coworkers have developed ... of a protein ( Chem. Sci. , 2014, ...
(Date:4/23/2014)... are often displayed in the popular Swedish children,s ... of high-sugar foods. A new study from the ... in children,s TV programmes as well as the ... and weight status. , Steingerdur Olafsdottir,s doctoral thesis ... popular Swedish children,s TV show Bolibompa. Healthy foods ...
(Date:4/23/2014)... led by a researcher from the Cancer Science Institute ... Singapore has identified the cancer specific stem cell which ... of developing new drugs for the treatment of this ... group, led by Dr Chan Shing Leng, Research Assistant ... that a cancer-specific variant of a cell surface protein, ...
(Date:4/23/2014)... in the journal Oncotarget , explored tumour ... or their own DNA signatures within the same ... design effective, targeted treatment strategies. , Firstly they ... and either the KRAS or BRAF mutation. Secondly, ... EGFR gene mutation have that specific mutation present ...
(Date:4/23/2014)... Alzheimer,s disease has been a rapidly evolving pursuit ... latest crook in the research road, scientists have ... proteins associated with the disease. The report, which ... , could have important implications for developing novel ... colleagues explain that for years, research has suggested ...
Breaking Medicine News(10 mins):Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:High-calorie and low-nutrient foods in kids' TV 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ...
(Date:1/14/2014)... InformEx, North America,s leading business partnering ... the 30 th edition of its annual conference at ... January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... and specialty chemical companies will take part in the conference, ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
Cached News: